RxDoctor Payments Data

Usman Javed, MD

Cardiovascular Disease · Fresno, CANPI 1770592578

Payments from drug & device makers

$20,287in general payments, 2019–2025

Across 272 payments — averaging $74.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$13K
  • Edwards Lifesciences$3K
  • Amgen$869
  • Shockwave Medical, Inc$662
  • Abiomed$569
  • Boston Scientific$436
  • plus $2K from 12 others

What the payments were for

  • Consulting fees$8,10040%
  • Travel & lodging$3,55418%
  • Food & beverage$8,63343%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,287 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$2,343,911
Medicare patients
2,873
Services billed
15,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan732$966,268
EliquisApixaban772$965,279
FarxigaDapagliflozin Propanediol585$643,510
Repatha SureclickEvolocumab774$597,910
XareltoRivaroxaban120$168,848
JardianceEmpagliflozin132$155,264
WegovySemaglutide39$63,389
OzempicSemaglutide44$42,794
VascepaIcosapent Ethyl56$40,982
DapagliflozinDapagliflozin Propanediol51$33,386
Praluent PenAlirocumab43$30,134
Metoprolol Succinate1,722$26,755
VerquvoVericiguat21$26,558
BrilintaTicagrelor23$25,110
Icosapent Ethyl71$23,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$400$966,268732 claims
PfizerEliquis$148$965,279772 claims
AstraZenecaFarxiga, Brilinta$238$668,620608 claims
Johnson & JohnsonXarelto$28$168,848120 claims
MerckVerquvo$13$26,55821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →